BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

  • The 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th at 8:45 a.m. ET
  • The BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10th at 6:00 p.m. ET
  • The JMP Securities Life Sciences Conference in New York on Tuesday, May 16th at 2:30 p.m. ET
  • The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 17th at 8:00 a.m. ET

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at .

BCRXW

Contact:

John Bluth



 



EN
12/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE

BioCryst to Report Third Quarter 2025 Financial Results on November 3

BioCryst to Report Third Quarter 2025 Financial Results on November 3 RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available...

 PRESS RELEASE

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE...

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch